Karbicombi

Hydrochlorothiazide and Candesartan cilexetil, the active ingredients in Karbicombi, are a thiazide diuretic and an angiotensin II receptor blocker presented as an oral tablet for systemic use. They are used to lower elevated blood pressure in adults.

GNH USA supplies Karbicombi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Karbicombi combines a thiazide diuretic and an angiotensin II receptor blocker to treat hypertension.

- Essential hypertension: helps achieve target systolic and diastolic blood pressure levels. - Secondary hypertension: provides additional blood‑pressure control when underlying causes are addressed. - Hypertension in patients with diabetes: offers effective pressure reduction while minimizing metabolic side effects.

Common Side Effects: - Dizziness or light‑headedness - Headache - Increased urination - Electrolyte disturbances (e.g., low potassium, low sodium) - Fatigue - Mild cough

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute kidney injury - Hyperkalemia - Angioedema (swelling of face, lips, tongue) - Hepatic dysfunction - Severe hypotension

Karbicombi should be used with clinical monitoring and awareness of patient‑specific factors. - Electrolyte monitoring: check potassium and sodium levels regularly. - Renal function: assess creatinine and eGFR before and during therapy. - Hepatic impairment: use with caution in patients with severe liver disease. - Gout: thiazide component may increase serum uric acid; monitor gout patients. - Pregnancy and lactation: consult a physician before use. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Karbicombi may interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Potassium supplements or potassium‑sparing diuretics: risk of hyperkalemia. - ACE inhibitors or other ARBs: additive effect on potassium and renal function. - Lithium: increased lithium levels and toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive efficacy and affect renal function. - Beta‑blockers: may enhance blood‑pressure lowering effect, requiring dose adjustment.